On Thursday, AbbVie Inc (NYSE:ABBV)’s shares declined -10.35% to $48.26.
AbbVie Inc (ABBV) is currently valued at $89.10 billion. The company has 1.66 billion shares outstanding and 75.20% shares of the company were owned by institutional investors. The company has 3.81 value in price to sale ratio while price to book ratio was recorded as -14.20. The company exchanged hands with 46.52 million shares as compared to its average daily volume of 10.06 million shares.
In consultation with the U.S. Food and Drug Administration (FDA), the U.S. Product Inserts (USPI) for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) have been updated from ‘not recommended in Child Pugh B patients’ to a contraindication in patients with Child-Pugh B cirrhosis. Patients classified as Child-Pugh C will remain contraindicated as they have been since approval.
The updated USPI for VIEKIRA PAK also comprises a recommendation for physicians to assess evidence of hepatic decompensation before treatment and during treatment in cirrhotic patients.
Because post-marketing events are stated voluntarily during clinical practice, estimates of frequency cannot be made and a causal relationship between treatment and these events has not been established.
VIEKIRA PAK with and without ribavirin (RBV) remains indicated for genotype 1 (GT1) HCV patients with compensated cirrhosis, counting Child-Pugh A. The safety and efficacy of VIEKIRA PAK, with and without RBV, has been studied in Phase 3 trials in more than 2,300 patients and is one of the recommended regimens in the AASLD guidelines for these patients. TECHNIVIE in combination with RBV is indicated for genotype 4 (GT4) HCV patients without cirrhosis.
AbbVie will issue a Dear Health Care Provider letter to inform US healthcare providers of the updates.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, counting rheumatoid arthritis, psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone.
Boston Scientific Corporation (NYSE:BSX)’s shares dropped -4.48% to $16.42.
Boston Scientific Corporation (BSX) offered 33.30% EPS for prior five years. The company has -2.40% return on equity value while its ROI ratio was 0.80%. The company has $23.10 billion market capitalizations and the institutional ownership was 91.70%. Its price to book ratio was 3.34. Volatility of the stock was 2.77% for the week while for the month booked as 2.75%.
Baxter International Inc. designated Boston Scientific Corp. Chief Executive Officer Mike Mahoney to its board, adding a director who turned around one of the nation’s biggest medical-device companies, according to Bloomberg.
The move comes as Deerfield, Illinois-based Baxter is looking for a new leader of its own. CEO Robert Parkinson declared his plans to step down earlier this year after spending more than a decade at the company. Mahoney’s nomination was encouraged by Third Point LLC, Baxter’s biggest shareholder, which played a role in recruiting him, according to a person familiar with the deliberations who declined to be identified discussing non-public information.
Third Point wants Baxter to replicate Mahoney’s track record at Marlborough, Massachusetts-based Boston Scientific, where he returned the company to growth after a four-year losing streak, boosted operating margins and shifted into faster-growing product areas. He joins Third Point partner Munib Islam on the board and fulfills the company’s Sept. 30 agreement to appoint a second independent director to the group. Bloomberg Reports
Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which comprises Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others;
At the end of Thursday’s trade, J C Penney Company Inc (NYSE:JCP)‘s shares surged 1.63% to $9.97.
J C Penney Company Inc (JCP) has market value of $2.99 billion while its EPS was booked as $-1.81 in the last 12 months. The stock has 305.49 million shares outstanding while 85.20% shares of the company were owned by institutional investors. In the profitability analysis, the company has gross profit margin of 35.80% while net profit margin was -4.50%. Beta value of the company was 1.12; beta is used to measure riskiness of the security.
J C Penney Company, declared Thursday it will whittle down the staff at its headquarters by around 9 percent, according to Business Journals.
In a prepared statement, spokesman Joey Thomas said the Plano company will cut 300 of its 3,400 home office jobs as part of cost-cutting measures.
“As J.C. Penney works to achieve its financial growth targets, it is essential that our operations align with the planned priorities of the company,” Thomas said in the statement. “Over the last several months, the company has been evaluating its home office structure to identify opportunities for greater simplification and higher productivity. As the company continues to make progress on its planned framework and implement new processes and efficiencies, it is imperative that we maintain a thoughtful approach to managing expenses while effectively supporting the needs of the business.”
Since being hired as CEO-designee in November under former J.C. Penney CEO Mike Ullman, newly-designated CEO Marvin Ellison has stressed the importance of cutting costs, counting around supply chain and manufacturing efficiency. Business Journals Reports
J.C. Penney Company, Inc. is a holding company. The Company’s operating partner is J. C. Penney Corporation, Inc. (JCP). The Company’s business comprises of selling merchandise and services to consumers through its department stores and Website at jcpenney.com, which utilizes applications for desktop, mobile and tablet devices.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.